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Ischemic heart disease is the leading cause of death for women in the Western 
hemisphere. Women with ischemic heart disease typically present to the emergency 
department with acute coronary syndrome, and subsequently undergo coronary 
angiography. In 66% of women, no evidence of obstructive disease is found, and current 
standard of care recommends no further diagnostic testing. However, nonobstructive 
diseases cannot be ruled out with coronary angiography alone and therefore are 
frequently missed. This study will examine whether invasive physiological testing 
with coronary angiography can impact multiple adverse cardiac events in adult 
women. Using a prospective comparative effectiveness trial, we will compare the 
occurrence of these events at one year in adult women that undergo coronary 
angiography plus invasive physiological testing rather than standard of care. This study 
may help improve diagnostic accuracy and inform disease-specific treatment for women 
with nonobstructive coronary disease, as well as decrease healthcare utilization costs. 
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Chapter 1 – Introduction 
1.1 Background 
For women in the United States, and worldwide, as well, cardiovascular diseases 
(CVDs) remain the leading cause of death1-4. Yet despite this staggering fact, CVDs are 
largely understudied in women and often thought of as primarily impacting men1, leaving 
women out of critical research and a gaping hole in knowledge about how CVDs really 
impact women5. This is due largely in part to the fact that women often present 
differently from men with CVDs. While men present with the classic left-sided, crushing 
chest pain radiating to the left shoulder or arm, women tend to have more atypical 
symptoms such as dyspnea or weakness that can lead to a delayed presentation6-8. This 
delayed presentation can be as little as hours to days to present to the Emergency 
Department (ED), or even years later than men would typically present, and has been 
somewhat attributed to the decrease of estrogen with age and estrogen’s analgesic 
property, as well as reluctance to seek care for their symptoms or barriers to access1,5,9.  
Additionally, women presenting with acute coronary syndrome (ACS) are often 
underdiagnosed10. This is partially attributed to studies that have shown that the 
diagnostic cutoff for troponin levels is too high for typically presenting women, as men 
more often present with higher levels10. With this underdiagnosis, women are also less 
likely to receive coronary angiography or pharmacological treatment than men are for 
their ACS, leaving the etiology of their ACS both undiagnosed and untreated1,10. Patients 
have even been falsely told that there was nothing wrong with their heart when in fact 
further testing was not conducted to ensure this was true11. 
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1.2 Statement of the Problem 
 When women are able to receive a coronary angiogram, they are more likely to 
have nonobstructive disease (<50% stenosis)12-15. There are various causes for 
nonobstructive disease that are not able to be determined from coronary angiography 
alone, including but not limited to microvascular dysfunction and vasospastic angina12,16-
18. Coming to the correct diagnosis is important for implementing an effective treatment 
plan for patients, and yet the standard of care in current practice is to pursue no further 
diagnostic testing after obstructive coronary artery disease is ruled out on coronary 
angiogram, often resulting in women being falsely reassured that they do not have 
coronary dysfunction when that may not be true19,20. With only a diagnosis of 
nonobstructive disease and no further classification of disease, medical management is 
less likely to be used than in their obstructive coronary disease counterparts, in which 
there are evidence-based treatment guidelines including medications, revascularization, 
and cardiac rehabilitation21. There is no consistency across institutions in treating 
nonobstructive disease thanks in part to the lack of a well-classified diagnostic algorithm 
and an overall lack of research on these diseases21,22.  
Nonobstructive diseases have additionally been associated with higher rates of 
adverse cardiac events including stroke, myocardial infarction, heart failure, and even 
death, putting women disproportionately at risk for these adverse events and requiring 
further follow up/healthcare burden9,21-23. According to the Women’s Ischemia Syndrome 
Evaluation (WISE) study that has been conducted over the past 25 years, women with 
nonobstructive disease have a 13% overall mortality rate24. Much of these adverse events 
are in the setting of microvascular dysfunction, underscoring the importance of further 
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research into these nonobstructive diseases24. One crucial step in this process is to 
develop a diagnostic pathway for the various diseases that fall under the nonobstructive 
umbrella.  
In the recent Coronary Microvascular Angina (CorMicA) trial, Ford et al. utilized 
an interventional diagnostic procedure in patients that were found to have ischemia and 
nonobstructive disease on coronary angiography to determine if there was a subsequent 
decrease in angina using the Seattle Angina Questionnaire25. They found that by 
performing this interventional diagnostic procedure (which involves inserting a guidewire 
to infuse adenosine and acetylcholine into the great vessels of the heart) they were better 
able to diagnose nonobstructive diseases such as microvascular angina and vasospastic 
angina and stratify treatment more appropriately for each diagnosis. This subsequently 
led to improved angina and quality of life for patients that received this intervention25. 
This study in addition to the WISE trial are pivotal steps in suggesting further diagnostic 
workup for patient with nonobstructive disease to further classify the etiology of the 
ischemia and filling the gap in research. 
 
1.3 Goals and Objectives 
The goal of this study is to evaluate if coronary angiogram with invasive physiologic 
testing is a viable option for improving diagnostic phenotyping in women with acute 
coronary syndrome and nonobstructive coronary dysfunction. We will accomplish this by 
determining if coronary angiography with invasive physiologic testing compared to 
historical data from Connecticut hospitals on the standard of care (coronary angiography 
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alone) in women with ACS found to have nonobstructive coronary dysfunction impacts 
the occurrence of MACE in the year following intervention. 
The objectives of this study are to determine if coronary angiogram with invasive 
physiologic testing can lead to improved diagnostic phenotyping and personalized 
treatment strategies for women with ACS and nonobstructive coronary dysfunction, 
therefore leading to decreased subsequent MACE. Secondarily, we will also evaluate if 
coronary angiogram with invasive physiologic testing impacts each individual component 
of MACE in the year following the intervention. 
 
1.4 Hypothesis 
We hypothesize that women over 18 years old with acute coronary syndrome who are 
found to have no obstructive coronary artery disease on coronary angiography and who 
subsequently undergo invasive physiologic testing to diagnose the mechanism of acute 
coronary syndrome will have a statistically significant difference in occurrence of MACE 
at one-year post-procedure as compared to historical data on those that undergo coronary 
angiography alone and do not receive a definitive diagnosis. 
 
1.5 Definitions 
ACS: Acute Coronary Syndrome. The American Heart Association defines ACS as “an 
umbrella term for situations where the blood supplied to the heart muscle is suddenly 
blocked.” Patients will have a high clinical suspicion as well as a rise or fall in cardiac 
markers (at least two consecutive cardiac troponins). 
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MACE: Major Adverse Cardiac Events including recurrent angina pain, development of 
heart failure, non-fatal infarction, presentation to the Emergency Department with 
cardiovascular-related illness, admission to the hospital for cardiovascular-related illness, 
percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), 
stroke, and all-cause mortality. 
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Chapter 2 – Review of the Literature 
2.1 Introduction 
 An extensive review of the relevant literature was performed with help from the 
Yale University School of Medicine librarians in July 2020 and from November 2020-
December 2020. The databases utilized were Pubmed, Ovid Medline, Scopus, and The 
Cochrane Medical Library. Key search terms relating to our study population included 
“acute coronary syndrome,” ACS, coronary, women, female, adult, sex, angina, “chest 
pain,” and NSTEMI. Search terms related to our intervention included angiography, 
“coronary angiogram,” adenosine, acetylcholine, “stratified therapy,” vasospasm, 
microvascular, “microvascular angina,” MINOCA, and INOCA. Search terms relating to 
our outcome included “major adverse cardiac events,” MACE, outcomes, and “one 
year.” Finally, search terms related to our study type included “comparative 
effectiveness” and prospective. Searches were limited to adults over 18 and studies 
published in the last five years. Results were then screened for relevance to this study. 
 
2.2 Review of Sex Differences in Coronary Artery Diseases 
 There is a generalized paucity of research on coronary artery diseases in women 
that has only begun to rectify itself over the past few years. This is likely due in part to 
the differing pathophysiology of coronary artery disease in women and the increased 
likelihood of a nonobstructive diseases such as coronary microvascular dysfunction26,27. 
In 2015, Pepine et al. called attention to this gap in the literature with a position paper. 
They reference the Women’s Ischemia Syndrome Evaluation (WISE) study, which was a 
prospective cohort of 936 women with angina or suspicion for ischemia that underwent 
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coronary angiography, as the primary resource for data on nonobstructive disease in 
women26. Their study made huge initial strides in the way of shrinking the gender gap in 
research by conducting a study with only women participants over several years. Some of 
their findings include that about 66% of women enrolled were found to have 
nonobstructive coronary dysfunction and that for this group of women there was a yearly 
risk of 2.5% that MACE would occur26 with a 5 year rate of MACE around 11% 
(p<0.001)19.  
Although the WISE study is certainly impactful, it is not without limitations, as 
Pepine et al. point out, including a smaller sample size, selection bias including only 
women that have access to healthcare, and recall bias by utilizing a self-reporting system 
for MACE19,26. The WISE study was able to spur other studies, though, and similar 
studies have replicated the same trend of women with ACS being more likely to have 
nonobstructive diseases as well as worse outcomes26. Pepine et al. ended their position 
paper with a call to action to address further knowledge gaps going forward including 
being able to diagnose the mechanism behind ischemia as well as to stratify treatments 
specific to underlying etiologies of disease with more clinical trials26. 
 In 2016, Kawamoto et al. published a review on sex differences in ACS to 
evaluate the available data and studies at the time5. In this, they highlighted the very 
prevalent disparities between women and men and the high mortality rate that heart 
diseases pose to women, especially those with comorbidities and to minorities5. They also 
ended their review with a call for more research so that better diagnostic modalities and 
treatment algorithms can be developed for these high-risk populations5. This same year, 
Mehta et al. published the first statement from the American Heart Association regarding 
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myocardial infarction in women. They report that although mortality for women with 
cardiovascular diseases has been declining in the past 15 years thanks to heightened 
awareness, it is still killing women at higher rates than men1. They also highlight that 
women are undertreated with current guidelines and have worse outcomes than their male 
counterparts, further endorsing the need for more targeted research1. 
 There is also copious evidence that women presenting with ACS are less likely 
than men to receive a coronary angiogram or to be diagnosed with any type of 
myocardial infarction1,10. This is likely due in part to cardiac troponin (cTn) levels 
varying between women and men and women being less likely to reach the threshold for 
diagnosis10. However, in a 2018 study in Canada, researchers studied patients presenting 
to the Emergency Department with chest pain to evaluate if cTn levels could account for 
the differences in diagnosis and outcomes between men and women. They found that 
even in men and women that presented with ACS and met the cTn criteria for a 
myocardial infarction, women were still less likely to receive a coronary angiogram, be 
diagnosed with a myocardial infarction, had higher rates of MACE, and were less likely 
to be appropriately treated for their disease10. They do speculate that the higher rates of 
MACE may be related to the higher rates of comorbid conditions in women, as the 
difference did not persist and was no longer statistically significant when these conditions 
were corrected for10. However, this was a novel study with a large sample size (7,272 
participants) that showed statistically significant sex differences, and though not without 
limitations such as lack of generalizability to patients without chest pain and use of coded 
data, it is a step in the right direction and emphasizes that further research is warranted to 
examine why these sex differences persist and what can be done about them10. 
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 Conversely, in a 2018 study of patients with total obstructive coronary lesions 
evaluating MACE after receiving PCI found that male participants had a decrease in 
MACE over three years while female participants saw no change in MACE2. They 
partially attribute this to complications that occurred during PCI being significant 
predictors of 3-year mortality on multivariate Cox regression for women but not for 
men2. This indicates that even for women with obstructive disease, the mortality risk is 
higher after undergoing what is meant to be a lifesaving procedure, and continuing to 
treat women the same way men are treated is not sustainable and instead may be putting 
them at further risk. This is a German study that, while retrospective and not necessarily 
representative of the overall female population, spanned nine years and had a large 
sample size (2002 participants) making it important to consider. A similar study 
conducted in the US in 2019 did not find any sex differences in outcomes post-PCI for 
participants with total obstructive lesions7. This study, however, utilized a registry for 
reporting outcomes, only had 1000 participants (196 of which were women), and only 
evaluated MACE at 1 year as compared to the German study, subjecting this study to 
potential biases and limitations7. 
 Another study of 21,375 participants in India published this year examined sex 
differences in cardiovascular disease patients and found that women had more risk factors 
including diabetes and hypertension, had a later presentation to care, and were less likely 
to be treated28. They additionally had a 53% increased risk of in-hospital MACE 
(adjusted RR 1.53, 95% CI 1.32-1.77, p<0.001) and a 39% increased risk of MACE 30 
days afterwards (adjusted RR 1.39, 95% CI 1.65-2.07, p<0.001) than the men in the 
study28. In terms of mortality, women were 67% more likely to die in the hospital 
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(adjusted RR 1.67, 95% CI 1.42-1.97, p<0.001) and 48% more likely to die within 30 
days (adjusted RR 1.48, 95% CI 1.29-1.70, p<0.001) than men28. This study found 
significantly worse outcomes for women all around, even when adjusting for baseline 
characteristics. Although India is a vastly different country than the United States, this 
just further highlights this staggering issue worldwide. The ultimate goal for sex 
differences in coronary dysfunction is to develop diagnostic algorithms that benefit 
women specifically, as the current standard of care throughout the world is not working 
well enough for women now8. 
 
2.3 Review of Nonobstructive Coronary Dysfunction 
 The general consensus in the literature, and even from the European Society of 
Cardiology and the American Heart Association/American College of Cardiology, is that 
nonobstructive disease is considered to be <50% vessel obstruction with elevated cardiac 
biomarkers (usually cTn)12-15. Another term that is often used in the literature is 
MINOCA, or myocardial infarction with no obstructive coronary artery disease. The 
specific nature of this terminology, though, implies there is a component of MI/ischemia 
occurring, which is not the case for all patients presenting with acute coronary syndrome, 
but is certainly one of the most dangerous diagnoses15. For the purposes of our study, we 
will continue to refer to our participants as those with nonobstructive coronary 
dysfunction rather than restricting them to the MINOCA umbrella. 
The recent rise in nonobstructive coronary dysfunction, particularly in women, is 
likely multifactorial. Not only do we have an aging population in which NSTEMIs are 
more common than STEMIs, but also by relying more heavily on cTn as a biomarker of 
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ischemic disease rather than creatinine kinase-myocardial isoenzyme (CK-MB), more 
disease processes are being classified as NSTEMIs rather than unstable angina6,15,29. In 
addition to this rise in prevalence is the theory that nonobstructive disease are more 
dangerous than originally thought, and with this danger comes an increasing need to 
further classify the underlying etiology9. In their 2018 review, Makarovic et al. proposed 
to classify nonobstructive disease by whether they are ischemic (Type I) or nonischemic 
(Type II) in which ischemic diseases are further differentiated as endothelium dependent 
(1A), endothelium independent (1B), or vasoconstrictive (1C) and nonischemic diseases 
are further differentiated as neurogenic afferent (2A), neurogenic efferent (2B), or 
habitual (2C)9. This proposed classification system is another step in the right direction 
and even suggests different clinical presentations patients may express, but ultimately is 
not useful without effective means of diagnosis, again highlighting the need for further 
studies proposing accurate diagnostic modalities. 
 In a recent statement from the American Heart Association, Tamis-Holland 
(Chair) et al. published in 2019 a proposed clinical algorithm called the “Traffic Light” 
Sequence to help diagnose nonobstructive disease that offers various diagnostic 
modalities depending on clinical presentation15. This algorithm includes considering non-
cardiac causes of elevated cTn and nonobstructive disease as well as alternate diagnoses 
such as obstructive disease, dissection, Takotsubo cardiomyopathy, and myocarditis15. 
They recommend noninvasive techniques such as Echocardiogram or cardiac MRI if less 
suspicious for MINOCA, but for nonobstructive coronary dysfunction such as coronary 
vasospasm or microvascular disease, more invasive strategies are recommended 
instead15. This proposed algorithm is one of the first of its’ kind, and it carries a lot of 
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weight coming from the American Heart Association. It can help clinicians to make 
important strides in getting to the root cause of coronary dysfunction and then prescribe 
appropriate treatment regimens and improve overall outcomes15. Our proposed study 
would be applying part of this algorithm as our participants would have a high suspicion 
for nonobstructive dysfunction on presentation, being all women with ACS, and could 
provide further evidence for widespread implementation of this diagnostic algorithm or 
something similar.  
This novel statement also suggests potential therapies for the variety of etiologies 
that could be diagnosed if this diagnostic algorithm was implemented, a field which is 
also in desperate need of further clinical trials as the diagnostic research is 
progressing15,30. Some of their suggestions based on what research is currently available 
include aspirin and another antiplatelet agent for plaque disruption, calcium channel 
blockers for coronary vasospasm, and calcium channel blockers and beta blockers for 
microvascular dysfunction15. The Women’s IschemiA Trial to Reduce Events in 
NonObstructive CAD (WARRIOR) trial is a new study currently in progress that aims to 
further examine the best treatment pathways for women with nonobstructive coronary 
dysfunction31. This trial is multicenter, prospective, and randomized with a blinded 
outcome evaluation, and is comparing intensive medical therapy with statins and 
angiotensin converting enzyme inhibitors (ACE-I) or receptor blockers (ARB) to the 
current standard of care on the occurrence of MACE31. Hopefully the results of this trial 




2.4 Review of Diagnostic Modalities for Nonobstructive Coronary Dysfunction 
 Although there is no true consensus on the best diagnostic modality for 
nonobstructive coronary dysfunction, there have been more recent studies on noninvasive 
techniques such as cardiovascular magnetic resonance (CMR), computed tomography 
(CT), and functional stress testing8,32-34. Additionally, Positron emission tomography 
(PET) myocardial perfusion imaging (MPI) can also quantify coronary flow reserve 
(CFR) of coronary vessels and is thought to be useful in prognosis and risk assessment, 
especially as more facilities are combining PET and CT8. These imaging techniques aim 
to do a similar job as a more invasive testing procedure with the added benefits of being 
less limited by cost and perhaps more accessible. However, for our study, the participants 
we are recruiting would be receiving an invasive coronary angiogram regardless, and the 
additional invasive procedure we propose would not add much time or effort to what is 
already being done. Patients that do not require coronary angiogram initially may be 
better served by these noninvasive techniques. 
 In the WISE study, one of the more invasive diagnostic modalities they tested was 
coronary reactivity testing (CRT) in which acetylcholine was infused in various 
concentrations into the coronary arteries (specifically the left anterior descending or 
LAD) of patients with ACS and nonobstructive coronary dysfunction and pressures were 
measured in the left ventricle and aorta to look for microvascular disease20,35-37. They 
then examined subsequent adverse events and MACE, finding that only two participants 
(0.7%) had serious in-procedure events of dissection from the doppler wire not requiring 
intervention and a focal coronary spasm prior to acetylcholine infusion treated with 
nitroglycerin20. Another two women (0.7%) had adverse events in procedure which were 
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a transient air microembolism that resolved with supplemental oxygen and a deep vein 
thrombosis (DVT) a month afterwards that resolved with anticoagulation20. As for 
MACE in these participants, which included, death, MI, stroke, or hospitalization for 
heart failure, there was a rate of 8.2% in the following five and a half years20. The low 
rates of serious and general adverse events in-procedure and right afterwards is reassuring 
for an invasive procedure in a high-risk population. 
 In the WISE trial, to discuss this first invasive intervention more specifically, 
assessing microvascular reactivity with CFR was measured by injecting adenosine in two 
increasing amounts into the coronary arteries and taking a ratio of peak velocity to rest 
velocity with each infusion (CFR > 2.32 was considered normal)23. When examining 
MACE with this technique, rates of MACE over 10 year follow-up were increased in 
participants with a low CFR (p = 0.008 for 3-component MACE and p = 0.028 for 4-
component MACE) and low CFR levels independently, statistically significantly 
predicted the 4-component MACE even when corrected for baseline characteristics (HR 
1.06, 95% CI 1.004-1.12, p = 0.035)23. Although this trend of low CFR being a predictor 
of MACE has been previously established, and that CFR is often lower in women38, this 
study was able to replicate it with longer-term follow-up. The authors again reiterate that 
although these procedures are invasive, they are fairly safe with low rates of 
complications or adverse effects, making them a considerable option for going women 
with ACS and nonobstructive coronary dysfunction23,39. 
 Another invasive technique used to further evaluate the underlying etiology of 
nonobstructive coronary dysfunction in the WISE study is to infuse acetylcholine to 
assess for vessel reactivity and coronary vasospasm40. They did this by infusing 
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acetylcholine into the coronary arteries for two three-minute periods then measuring 
blood flow, pressure, and vessel diameter to assess for changes23. With this technique, the 
researchers found that decreases in coronary blood flow by 10% increased the mortality 
risk by 23% (HR 1.23, 95% CI 1.04-1.45, p = 0.015), as well as a 16% increase in both 4-
component and 3-component MACE (HR 1.16, 95% CI 1.06-1.27, p = 0.001 and HR 
1.16, 95% CI 1.05-1.28, p = 0.003 respectively)23. All this is to say that this invasive, 
reasonably safe technique appears to be effective in identifying participants with 
coronary arteries prone to vasospasm that puts them at higher risk for MACE. The 
authors do reiterate here, though, that testing requires specific training and is not very 
cost effective, despite its diagnostic effectiveness. Additionally, results here may be 
skewed because even though coronary dysfunction was further characterized, because 
there is no universal treatment algorithm for these types of diseases yet, many of the 
participants went without treatment and this could have impacted the occurrence of 
adverse outcomes as well23. 
 
2.5 Review of Relevant Methodology 
 The following sections will review current literature and the methodology used 
relevant to this proposed study. 
 
2.5.1 Selection of Intervention 
 As previously discussed, while more research is being conducted on less invasive 
testing recently, invasive testing such as the proposed additional physiologic testing after 
coronary angiogram seems to be effective in further characterizing nonobstructive 
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coronary dysfunction. Not only is this evident in the WISE trial, but another trial titled 
the CorMicA trial that was conducted in 2018 utilized a similar intervention in both men 
and women12,23. They called their intervention an “interventional diagnostic procedure” 
in addition to coronary angiography which involved assessing the LAD coronary artery’s 
coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and fractional 
flow resistance (FFR) (to determine a lesion’s functional significance41) while infusing 
adenosine to evaluate microvascular dysfunction, as well as evaluating for coronary 
vasospasm while infusing acetylcholine12. They examined the effect of this on subsequent 
angina using the Seattle Angina Questionnaire, finding that angina was improved in those 
that received the procedure in their randomized controlled trial12. This study was another, 
similar to the WISE study, that showed an invasive procedure that had a positive impact 
on outcomes for its nonobstructive coronary dysfunction participants. As there are many 
hospitals across the state of Connecticut with coronary angiography capability staffed by 
very capable interventional cardiologists that perform similar interventions daily, we 
chose to mimic our own intervention after Ford et al.’s in the CorMicA trial to build upon 
the data they have already compiled.  
Additionally, a study conducted by Ahmed et al. on the safety of FFR and IMR 
measurements with adenosine found that adverse effects were self-limited and serious 
events such as STEMI, NSTEMI, and dissection were exceedingly rare, reinforcing the 
overall safety of our chosen procedure42. A study by Fearon et al. touted IMR as a widely 
available quantitative, and easily reproducible diagnostic strategy and found IMR > 40 to 
be stronger predictor of adverse outcomes43. This same trend was recognized in a trial by 
Fahrni et al. in 201744. Garcia et al. advocated for the use of FFR and CFR together in 
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tandem to get the best picture of what is happening in the coronary arteries, as we 
propose to do in our study45. 
 
2.5.2 Selection of the Outcome 
 Many of the studies we have previously discussed have evaluated MACE as their 
outcome. While we are basing our intervention on the CorMicA trial, their primary 
outcome is the Seattle Angina Questionnaire and only examined angina in patients12. By 
using MACE, we can include angina along with other adverse outcomes patients with 
ACS and nonobstructive coronary dysfunction are likely to have such as stroke, 
healthcare utilization, and even death from a cardiovascular cause. This is also a hard 
outcome that can be measured from hospital system EMR rather than a subjective 
questionnaire filled out by the patient themselves and not as subject to recall bias. Other 
studies that have chosen MACE as their primary outcome include a 2019 study in China 
by Abdu et al. examining MI in MINOCA patients and a 2020 study by Dreyer et al. 
examining Medicare patients with MINOCA compared to those with obstructive MIs46,47. 
Both studies found that older patients with MINOCA had worse outcomes46,47. Other 
studies using MACE as their outcome have found the opposite trend, that MINOCA 
patients had lower rates of MACE than obstructive disease patients, such as one study in 
Spain by Garcia-Blas et al. and another in Poland by Zandecki et al.48,49. Regardless, 
though, using MACE as our primary outcome like many other studies have allows us to 
compare and contrast results with others in the field to ultimately contribute to a wider 
body of knowledge. Additionally, by breaking down each individual component of 
MACE as our secondary outcome, we can also compare data to other studies that use 
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various combinations of MACE because MACE is defined slightly differently for each 
specific study. 
 
2.5.3 Selection of the Study Population 
 While several studies, including the CorMicA trial, recruited both men and 
women for their studies, the general trend is that nonobstructive diseases 
disproportionally impact women12. Even in the CorMicA trial, about 74% of all patients 
were women12 and the nature of the WISE study was to recruit only women, as well. As 
also previously stated, women and men have differing pathophysiology of disease, and by 
recruiting solely women, who are also understudied as a whole, we can minimize any sex 
differences that may have been playing a role in the outcomes of studies the recruited 
both sexes. This also contributes to the novelty of this study as a whole, being that there 
are so few studies that only recruited women. 
 As far as choosing baseline characteristics for our study population, we chose 
many that were similar to those in the CorMicA study such as age, medication usage, 
comorbid conditions such as diabetes and dyslipidemia, smoking status, and BMI. We 
also added some of our own that we thought may be interesting or potentially 
contributory and would need to be controlled for in multivariate analysis such as 
psychosocial factors, menopausal status, marital status, and prior therapies12. Many of 
these baseline characteristics were also collected in other studies such as the WISE 
study19,23,50. 
 
2.5.4. Selection of Study Type 
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 While much of the current literature consists of randomized clinical trials or 
cohort studies, we decided to go in a different direction and make our study a 
comparative effectiveness trial. By using this type of trial, we are able to rely on 
historical data from the hospitals we choose as our “control group” and enroll every 
eligible participant into the intervention we are proposing51. This eliminates the need for 
any blinding and helps us to achieve the appropriate sample size and power within the 
year-long time frame. This type of study also contributes to the novelty of our research, 
as in the literature searching, we were unable to find other studies that were conducted 
this way for female patients with nonobstructive coronary dysfunction. The closest study 
found was one by Kishi et al. in 2020 that examined the relationship between plaque 
burden in coronary arteries evaluated cy cardiac CT and MACE that utilized a 
comparative effectiveness study design52. They found success through achieving 
statistical significance in their several of their results with this model and its feasibility of 
comparing a novel intervention to the current standard of care, just as we propose to do52. 
 
2.7 Conclusion 
 Overall, there are very clear gaps in the literature as far as nonobstructive 
coronary dysfunction in women. Women as a whole are understudied in this field, as well 
as more likely to have nonobstructive disease rather than obstructive. Nonobstructive 
diseases additionally require diagnostic modalities that are not only accessible and 
feasible, but also that are effective enough to further characterize the underlying 
mechanism of disease so that patients can get appropriate treatment which should, in turn, 
improve outcomes such as MACE. The proposed study aims to do just that, 
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implementing additional invasive physiologic testing for women with ACS that are likely 
to have nonobstructive disease in hospitals across Connecticut to determine if there is an 
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Chapter 3 – Study Methods  
3.1 Study Design 
The proposed study will be a multicenter, single-arm, prospective comparative 
effectiveness clinical trial. We will target hospitals in the state of Connecticut that have 
coronary angiography capability by working with the states’ two largest healthcare 
systems, Yale New Haven Health and Hartford Healthcare. These hospitals would 
include Yale New Haven Hospital, Greenwich Hospital, Bridgeport Hospital, Lawrence 
and Memorial Hospital, and Westerly Hospital within the Yale New Haven Health 
System, as well as Hartford Hospital, Backus Hospital, The Hospital of Central 
Connecticut, St. Vincent’s Hospital, and Windham Hospital within the Hartford 
Healthcare System. Because this is a comparative effectiveness trial, we would enroll 
every patient able to give informed consent and meeting inclusion criteria into the 
intervention and compare outcomes with historical data on MACE rates from the WISE 
trial for women that underwent coronary angiography alone without further physiologic 
testing19. The total proposed timeline for the study would be 24 months with an 11-month 
recruitment period and 12-month follow-up period to assess for occurrence of MACE. 
Hospital Electronic Medical Record (EMR) system will be used to monitor for MACE in 
the following year. Both hospital systems use Epic for their EMR. 
 
3.2 Study Population and Sampling 
Because women are frequently left out of clinical trials and the evidence-based 
medicine is tailored to male participants, our study would solely recruit women. The 
study population would include women over the age of 18 presenting to Connecticut 
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hospitals (with coronary angiography plus invasive physiologic testing capability) with 
acute coronary syndrome and found to have nonobstructive disease on coronary 
angiogram. We will sample using convenience sampling so that any woman coming 
through the hospital doors with acute coronary syndrome will be recruited, contingent 
upon their initial coronary angiogram results showing nonobstructive disease. Including 
all hospitals from the two largest health systems in Connecticut that have coronary 
angiogram capability increases the likelihood that we will have a representative sample 
for adult women in the state of Connecticut. These 10 hospitals are spread throughout the 
state, and if women with acute coronary syndrome presented to a smaller hospital within 
the same system, they would need to be transferred to a hospital with coronary 
angiography capability regardless, so these women would be accounted for as well. 
Additionally, the nature of a comparative effectiveness study is that every woman with 
the potential to be included will have the opportunity to be included, as the “control 
group” is historical data from prior patients at each participating hospital, making the data 
more generalizable than in a randomized controlled trial which can be subject to internal 
bias. Women will be excluded from the study if they are found to have non-cardiac 
angina, Takotsubo cardiomyopathy, or an ST-elevation myocardial infarction (STEMI).  
 
3.3 Subject Protection and Confidentiality  
 Prior to the beginning of the study, institutional review board (IRB) approval will 
be obtained through the Yale University School of Medicine. The procedure described in 
section 100 PR.1 Review by a Convened IRB will be followed while submitting an 
application. This application will include a detailed protocol, a plan and materials for 
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recruiting, consent forms, Health Insurance Portability and Accountability Act (HIPAA) 
forms, and a funding application. Consent forms (Appendix 1) will be given at the time 
of recruitment on presentation to the Emergency Department to either the participant or 
their healthcare proxy with clearly outlined study protocols as well as any potential 
benefits and risks for participating in the study. While it may be challenging to obtain 
informed consent in an acute setting, the patient will already be consenting for a coronary 
angiogram to be performed, so we would come in afterwards to explain the additional 
testing and to answer any questions or concerns participants may have. All patient data 
will be stored on an encrypted server and de-identified of protected health information 
where possible, closely following all HIPAA guidelines. 
 Because our study has the potential to include pregnant patients and those of 
childbearing age, extra precautions will be taken to protect this vulnerable population. 
We will follow section 330.1 Requirements for Approval of DHHS-funded Biomedical or 
Behavioral Research Involving Pregnant Women or Fetuses to do so, as it is important to 
include potentially pregnant patients in our study population because MACE may cause 
significant harm to both mother and fetus, and the goal of this study is for our 
intervention to impact subsequent MACE. Additionally, the risks associated with a 
woman experiencing MACE outweigh those of performing additional physiologic testing, 
making it ethical to include these women in the study population. 
 
3.4 Recruitment 
 By utilizing convenience sampling, we will recruit every adult woman over age 
18 that meets inclusion criteria presenting with ACS to the aforementioned Connecticut 
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hospitals with coronary angiography capabilities. Participants will be consented prior to 
coronary angiogram and will remain in the study to receive the additional physiologic 
testing if they are found to have nonobstructive disease in their major coronary arteries. If 
a participant presents with a STEMI on EKG or is found to have obstructive coronary 
artery disease, Takotsubo cardiomyopathy, or a non-cardiac cause of ACS, they will also 
be removed from the study population and will not receive the intervention. 
 
3.5 Study Variables and Measures 
The intervention will be performing coronary angiogram plus invasive 
physiologic testing of the left anterior descending artery (LAD). The invasive physiologic 
testing involves inserting a pressure wire to measure coronary reserve flow (CRF), index 
of microcirculatory resistance (IMR) and fractional flow reserve (FFR) while infusing 
adenosine (to assess for functionally obstructive epicardial disease and microvascular 
dysfunction) and acetylcholine (to detect coronary vasospasm). This intervention is 
described in more detail by Ford et al. for the CorMicA trial, and we will be modeling 
our intervention after theirs12. 
The primary endpoint for our study will be occurrence of MACE at one year after 
the invasive physiologic testing is performed. This is a dichotomous variable, as 
participants will either have MACE occur, or they will not. Secondary outcomes will 
include the median number of each individual MACE component that occurs over one 
year to examine each component on its own as compared to any MACE as a whole. 
 
3.6 Blinding  
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 Our study does not have a control group and will instead be comparing the 
outcomes of our participants to historical data on adult female patients that presented 
with ACS, received a coronary angiogram, and was found to have nonobstructive disease 
from each participating hospital. Due to the lack of a control group, every participant will 
receive the intervention and therefore will not need to be blinded to it. Additionally, 
researchers and those evaluating the primary and secondary outcomes will not need to be 
blinded to the intervention the participant received, either, as all participants received the 
same intervention.  
 
3.7 Adherence 
 Adherence for our study primarily relies upon the training of qualified 
interventional cardiologists to perform the additional invasive physiologic testing while 
participants are undergoing coronary angiogram. We will target interventional 
cardiologists at participating Connecticut hospitals that have copious experience 
performing coronary angiograms and train them in the procedure before the recruitment 
period, so they are comfortable performing it for the study itself. Each provider will be 
required to attend a day-long training session, for which they will be compensated for 
their time, where they will be educated on the potential benefits of the procedure and all 
other study details, as well as given the opportunity to practice in a simulation. The 
invasive physiologic testing is at a similar level of complexity as a typical coronary 
angiogram, so it should not take the providers very long to feel comfortable performing 
it. We will also have a researcher observe the first two procedures each provider 
performers to assure consistency. 
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 As far as adherence for the participants, this is a one-time procedure, so the main 
factor will be reporting the occurrence of MACE, or any adverse effects experienced in 
the year following the procedure. As MACE are often events that would cause 
participants to seek healthcare53, we can primarily monitor this through hospitals’ EMR. 
Additionally, each participant will be given a researcher’s contact information to report 
any occurrence of MACE, and researchers will be instructed to reach out to each 
participant monthly by phone and/or email (by participant preference) to ask if MACE 
has occurred, and to remind them what MACE consists of. 
 
3.8 Monitoring of Adverse Events 
 In the CorMicA trial, there were very few adverse events recorded as a result of 
the intervention, and ones that did occur were considered minor or easily reversible12. 
The immediate adverse effects that we will need to monitor for during the procedure 
would be persistent atrial fibrillation, and paroxysmal atrial fibrillation secondary to 
acetylcholine. In the CorMicA trial, transient bradycardia and sinus pauses were not 
considered adverse events, but rather expected physiologic reactions to the procedure12. 
In the event that atrial fibrillation persisted and did not self-resolve within 30 minutes as 
occurred in the CorMicA trial for one patient, the interventional cardiologist would be 
advised to perform cardioversion with intravenous amiodarone while still in the cardiac 
catheterization lab to revert the patient back to sinus rhythm, which was successful in the 
CorMicA trial12.  
In the WISE trial, there were also very few adverse events. They reported one 
participant with a dissection from doppler wire insertion that did not require intervention, 
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one participant with a focal spasm prior to the invasive physiologic testing that resolved 
with nitroglycerin, one participant with a transient air microembolism that resolved with 
supplemental oxygen, and one participant that developed a DVT a month after the 
procedure that was effectively treated with anticoagulation20. These are all very low risk 
of occurrence, and all amenable to treatments that any cardiac catheterization lab would 
have at their disposal and that the interventional cardiologists would be capable of 
administering. 
 Additionally, the nature of our outcome (MACE) is that they are adverse 
outcomes in and of themselves. However, these outcomes are associated with patients 
with acute coronary syndrome and nonobstructive coronary dysfunction in general and 
may or may not be a direct result of our intervention20,46,47. Therefore, like any patient 
undergoing coronary angiogram, we will encourage our participants to both seek urgent 
medical attention in the setting of MACE occurring, as well as to later report this event to 
a researcher. As previously stated, we will also have researchers reaching out to 
participants monthly in addition to reviewing the EMR to assure we are aware of any 
occurrence of MACE. 
 
3.9 Data Collection 
 Data collection will occur continuously throughout this study. When participants 
are enrolled in the study (or soon after the intervention, depending on timing and urgency 
of coronary angiogram) baseline characteristics (detailed below) will be recorded. To 
collect data on our primary outcome, participants will need to give permission for us to 
view their EMR to monitor for the occurrence of MACE in the year following the 
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intervention. We will also have researchers reach out monthly to the participants by 
phone or email to assess for occurrence of MACE. The researcher will be required to fill 
out the Participant MACE Form (Appendix 2) for each participant during these monthly 
check-ins and evaluation of the EMR. All data collection information with be recorded on 
encrypted servers. If at any time a participant wishes to withdraw from the study, their 
associated information and data will be permanently deleted. 
 
3.10 Sample Size Calculation 
 To calculate sample size for this comparative effectiveness trial, we will be 
utilizing data from the WISE study and the Power and Sample Size Calculator provided 
online by the Department of Biostatistics at Vanderbilt University19. From the WISE 
study, their primary composite endpoint was cardiovascular events including MI, and 
hospitalization for heart failure, stroke, or cardiac mortality which is similar to our 
proposed MACE outcome19. They found that about 2% of the asymptomatic (control) 
group met the primary composite endpoint while the symptomatic group was split into 
normal coronary arteries and nonobstructive coronary artery disease for which 8% and 
16% respectively met the primary composite endpoint19. To group these two symptomatic 
groups together, we found that 8% of 318 participants with normal coronary arteries is 
about 25 participants and 16% of 222 participants is about 35 participants, so added 
together, 60 of 540 participants or about 11% of symptomatic patients met the primary 
composite endpoint. We then calculated the sample size based on a power of 0.80 and a 
Type I (alpha) error of 0.05 estimating that the probability of the outcome for a control 
participant (p0) to be about 2% and the probability of the outcome for an experimental 
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participant (p1) to be about 11%. This gives us a sample size of 117 participants to reach 
this statistical power and Type I error. Detailed images and information regarding our 
sample size calculation can be found in Appendix 3. 
 
3.11 Statistical Analysis 
 Baseline characteristics (Table 1) for each participant that will be reported and 
analyzed will include age, comorbid conditions (history of CVD or stroke, diabetes, 
dyslipidemia, hypertension, severe COPD, overweight/obesity, or history of pregnancy 
complication such as hypertension, premature delivery, gestational diabetes, or 
preeclampsia), current medications (including statins, antihypertensives, antiplatelets, 
anti-ischemics, or cholesterol-lowering), cardiovascular risk factors (such as smoking), 
prior therapies (percutaneous coronary intervention or stents placed in the coronary 
arteries), psychosocial factors (such as perceived stress evaluated by the Perceived Stress 
Scale (PSS), depression evaluated by the Patient Health Questionaire-9 (PHQ-9), anxiety 
evaluated by the General Anxiety Disorder-7 (GAD-7), household income, food security, 
housing security, or transportation security), marital status, and menopause status. 
Dichotomous, categorical, and ordinal variables, such as comorbid conditions, 
medications, cardiovascular risk factors, prior therapies, psychosocial factors, marital 
status, and post-menopausal status will all be analyzed as proportions. Continuous 
variables including age is assumed to be normally distributed and will be analyzed as a 




Characteristic Type of Variable Number of Study Participants 
Age Continuous  
Comorbid Conditions – history 
of CVD or stroke, diabetes, 
dyslipidemia, hypertension, 
premature delivery, gestational 
diabetes, preeclampsia 
Dichotomous  





Cardiovascular Risk Factors (i.e. 
smoking) 
Dichotomous  
Prior Therapies (i.e. 
PCI/stenting) 
Dichotomous  
Psychosocial Factors – 
perceived stress, depression, 
anxiety, household income, food 
security, housing security, 
transportation security 
Categorical – Ordinal (stress, 
depression, anxiety, income) 




Post-menopausal Dichotomous  
Marital Status Categorical - Nominal  
Table 1. Baseline Characteristics of enrolled participants 
 The primary outcome, MACE, is a dichotomous variable and will be analyzed as 
a proportion using a Chi-square test for bivariate analysis. To consider any potential 
confounding effects of baseline characteristics as well as differences in care patterns by 
hospital, we will employ a hierarchical multivariate analysis using a logistic regression. 
The secondary outcomes will be the median number of each individual MACE 
component (recurrent angina pain, development of heart failure, non-fatal infarction, 
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presentation to the Emergency Department with cardiovascular-related illness, admission 
to the hospital for cardiovascular-related illness, repeat PCI, CABG, stroke, and all-cause 
mortality) that occurs over the one-year, post-intervention period and these are 
continuous, not normally distributed variables. They will be analyzed as means with 
standard deviations using a Student t-test. Significance will be defined as p<0.05. 
 
3.12 Timeline and Resources 
The timeline for this study will be a total of 24 months. After receiving IRB 
approval, we will aim to begin the study in January 2022. During the first month, we will 
properly train the interventional cardiologists that will be performing the invasive 
physiologic testing at each participating Connecticut hospital. There will be a day-long 
training at each hospital involving an overview of the study protocol, as well as a 
summary of potential benefits and adverse outcomes, followed by a question-and-answer 
session. There will then be an opportunity to practice the intervention through a virtual 
simulation. These clinicians will all be familiar with typical coronary angiogram, and 
because the procedure itself (infusing into and taking measurements of coronary arteries 
using a guidewire) is similar to standard practice, the one-day training period should be 
sufficient. However, we will have a researcher observe the first two sessions each 
provider conducts with study participants, as well as one subsequent random session, to 
assure consistency and that there are no further questions or clarifications. After this first 
month of training, we will begin the recruiting period for the next 11 months, cutting off 
enrollment at December 31, 2022 so as to allow for the full year of follow-up to assess 
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for the occurrence of MACE. From January 1, 2023-December 21 2023 there will be 
follow-up to assess for the primary and secondary outcomes.  
Relevant personnel will include a principal investigator to oversee all areas of the 
study. Additionally, we will need one research assistant assigned to each of the 10 
participating Connecticut hospitals respectively. They will be in charge of helping 
educate the interventional cardiologists prior to enrollment, the actual enrolling and 
consenting of participants at the beginning of the study, and monthly follow-up with 
patients and their EMR after the intervention to assess for occurrence of MACE. Lastly, 
there will be one physician assistant student assigned to fill in any gaps in data collection 
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Chapter 4 – Conclusion  
4.1 Advantages and Disadvantages 
This study has several strengths. Through the nature of a comparative 
effectiveness trial with every enrolled participant receiving the intervention and by 
targeting the two largest health systems in the state of Connecticut, I believe we will be 
reaching a large, diverse sample that is representative of the target population. This also 
means that every participant that enrolls has the opportunity to achieve the potential 
benefits of the additional invasive physiologic procedure. All of these factors make our 
study highly generalizable. Additionally, as a one-time procedure, there is minimal 
follow-up required for participants other than reporting if MACE occurs within the year 
after the procedure, which can also be cross-checked using each hospital system’s EMR. 
This decreases the likelihood that patients will be lost to follow-up as can be the case in 
studies that require more patient participation throughout the following year. 
Despite the many strengths, this study is not without limitations. One limitation of 
this study is the cost. While the goal of this intervention is to decrease adverse outcomes 
in the long-term for patients, which may result in less healthcare utilizations and saving 
money in that respect later, the up-front costs will be high. Firstly, we will need to train 
the interventional cardiologists performing the intervention and compensate them for 
their time, as well as make sure each cardiac catheterization lab has access to the proper 
tools and materials necessary for the intervention. We also need to compensate 10 
research assistants (one for each hospital site) and the primary investigator for the two-
year duration of the study. This is important research, though, that has the potential to 
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have a large, lasting impact on many patients, and with the proper time to apply for grant 
funding, we will be able to fund this study. 
Another potential limitation is obtaining informed consent in an acute 
environment. Although we are excluding patients with STEMIs that need to go to the 
cardiac catheterization lab urgently, we are recruiting patients that are in the ED for ACS 
and this can be a stress-inducing environment for patients and family members alike. 
However, as mentioned in Chapter 3, patients that qualify for our study will already be 
consenting to receive a coronary angiogram while in the ED regardless, and our 
researchers will be giving potential participants all study details including all known 
potential risks and benefits. They will also be sure to answer all questions and concerns 
the participant or healthcare proxy may have prior to enrollment to ensure they have all 
the information required to make an informed decision to participate or not. If at any time 
the participant chooses to leave the study after consenting, their information will be 
removed from encrypted servers, and they can be assured that they will continue to 
receive high quality care as per usual. 
 
4.2 Clinical and Public Health Significance  
This study has the potential to make a real difference, not just in the field of 
cardiology, but in clinical practice as a whole. As previously mentioned, CVDs are still 
the greatest cause of mortality for women across the world, and nonobstructive coronary 
dysfunction is more and more frequently the underlying cause1-3,12-15. In recent studies, 
invasive physiologic testing with acetylcholine and adenosine infusion into the coronary 
arteries to assess for microvascular dysfunction or coronary vasospasm, like we propose 
 43 
to implement here, has shown to be a safe, effective method of further characterizing the 
diagnosis of nonobstructive coronary dysfunction23. For many patients, a diagnosis can 
be life changing. Not only is coming to the correct diagnosis a potential answer to what is 
causing the patient’s symptoms, but it is also a critical step in getting the proper treatment 
for the underlying etiology of disease. With disease-specific treatment, we can impact 
overall outcomes for our patients, which can lead to less utilization of the healthcare 
system and decreased costs because adverse outcomes such as MACE are frequent 
reasons patients need to seek healthcare. If we can train interventional cardiologists 
across the country to perform this extra procedure while already doing a coronary 
angiogram in the absence of obstructive disease, women in every state could have 
decreased rates of MACE, including preventing unnecessary deaths. Admission to the 
hospital is a bad prognostic sign, and should be avoided where possible54-56. 
Providers in any field are likely to come across these patients, and with sound, 
evidence-based research like this proposed study to back up proposed diagnostic 
algorithms such as Tamis-Holland et al.’s “Traffic Light” Sequence15, providers can feel 
confident in recognizing the signs symptoms of ACS with a potential nonobstructive 
etiology and knowing what type of testing to order or referral to make. This study can 
also lay a strong foundation for further research in disease-specific treatment algorithms 
for nonobstructive coronary dysfunction, which is another area of up and coming 
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Appendix 1: EFIC Consent Form  
COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A 
RESEARCH STUDY 
YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 
Study Title: Coronary angiogram plus invasive physiologic tests in women with 
nonobstructive coronary dysfunction 
Principal Investigator (the person who is responsible for this research): Megan 
McCauley  
Phone Number: (413) 464-3510 
Research Study Summary:  
• We are asking you to continue being a part of our research study.  
• The purpose of this research study is to determine whether coronary angiogram 
plus invasive physiologic testing for women with acute coronary syndrome found 
to have nonobstructive coronary dysfunction results in a decreased occurrence of 
major adverse cardiac events (MACE) in one year. 
• Study procedures will include: Everyone in this study will receive a coronary 
angiogram and if there is less than 50% obstruction of the blood vessels in your 
heart by plaque buildup, you are considered to have “nonobstructive” coronary 
disease. You will then receive an additional invasive physiologic procedure that 
involves inserting a guidewire to infuse adenosine and acetylcholine to assess for 
any abnormalities and measuring pressures in the vessels. If you are found to have 
more than 50% obstruction, you will not qualify to participate in this study and 
will not receive the additional physiologic testing or be asked to follow-up with 
us. We will permanently delete all of your information from our encrypted 
servers. 
• There risks to participating in this study are minimal and reversible. Because it is 
a one-time procedure, the risks often happen at the time of the procedure and 
include atrial fibrillation that is reversible on its own or atrial fibrillation that 
requires a very effective medication called amiodarone to reverse. Very few 
participants in prior studies experienced this adverse effect. 
• Taking part in the continuation of this study is your choice. You can choose to 
take part, or you can choose not to take part in this study. You can also change 
your mind at any time. Whatever choice you make, you will not lose access to 
your medical care or give up any legal rights or benefits.  
• If you are interested in learning more about the study, please continue reading, or 
have someone read to you, the rest of this document. Take as much time as you 
need before you make your decision. Ask the study staff questions about anything 
you do not understand. Once you understand the study, we will ask you if you 
wish to continue to participate; if so, you will have to sign this form.  
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Why is this study being offered to me?  
We are asking you to take part in a research study because you are an adult female that 
came to the Emergency Department (ED) and your ED provider believes you are 
having an Acute Coronary Syndrome requiring a coronary angiogram. 
Who is paying for the study?  
Yale School of Medicine Physician Associate Program  
What is the study about?  
The purpose of this study is to evaluate if coronary angiogram with invasive physiologic 
testing is a viable option for improving diagnostic classification in women with acute 
coronary syndrome and nonobstructive coronary dysfunction. You have already 
consented to receive a coronary angiogram as part of your diagnostic workup for your 
acute coronary syndrome. The physician performing the angiogram will run a few extra 
tests if your coronary arteries show <50% obstruction. This includes infusing 
acetylcholine and adenosine into your coronary arteries and measuring pressures and 
taking measurements to observe for microvascular dysfunction or coronary vasospasm. 
What are you asking me to do and how long will it take?  
You are being asked to participate in this study because you are an adult female that met 
enrollment criteria by presenting to the ED with Acute Coronary Syndrome and are being 
referred for urgent coronary angiogram. While receiving a coronary angiogram in the 
cardiac catheterization lab, if your coronary arteries have from 0-49% obstruction with 
plaque, you are considered to have “nonobstructive coronary dysfunction” and qualify to 
continue participating in the study. While you are still in the catheterization lab under 
anesthesia, the interventional cardiologist that has been training in this procedure will 
perform additional invasive physiologic testing. This testing has been shown to be very 
safe with low risks of complications or adverse effects and has not increased hospital stay 
time. 
The additional invasive physiologic testing specifically involves inserting a pressure wire 
through your radial artery into your Left Anterior Descending (LAD) coronary artery to 
measure coronary reserve flow (CRF), index of microcirculatory resistance (IMR) and 
fractional flow reserve (FFR) while infusing adenosine (to assess for functionally 
obstructive epicardial disease and microvascular dysfunction) and acetylcholine (to detect 
coronary vasospasm). 
As this is a one-time procedure, the follow-up required would be reporting and Major 
Adverse Cardiac Events (MACE) that may or may not occur over the next year. MACE 
includes recurrent angina pain, development of heart failure, non-fatal infarction, 
presentation to the Emergency Department with cardiovascular-related illness, admission 
to the hospital for cardiovascular-related illness, percutaneous coronary intervention 
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(PCI), coronary artery bypass grafting (CABG), stroke, and all-cause mortality. You 
would give us access to your online medical record to determine if any of these events 
occurred to you and if so, how many. Additionally, you would allow a research assistant 
to reach out to you monthly to assess if one of these events occurred to you in the past 
month but did not cause you to seek medical care. 
What are the risks and discomforts of participating?  
There are minimal side effects associated with this additional invasive physiologic 
procedure reported in prior studies. Most reported were minor or easily reversible while 
still in the cardiac catheterization lab. 
Potential Adverse Events Reported from Prior Studies: 
One participant experienced a dissection (or false passage) of their coronary artery from 
pressure catheter insertion. This did not require any intervention as blood flow was not 
detrimentally impacted.  
Another participant experienced a focal spasm of their coronary artery after the coronary 
angiogram and prior to the invasive physiologic testing that resolved soon after with the 
administration of intravenous nitroglycerin.  
One other participant experienced transient air microembolism that resolved with 
supplemental oxygen. 
One more patient developed a deep vein thrombosis 1 month after the procedure that 
resolved with guideline-approved anticoagulation.  
A few patients also experienced transient atrial fibrillation that self-resolved. One patient 
had atrial fibrillation that persisted >30 minutes that resolved when give intravenous 
amiodarone while still in the cardiac catheterization lab. 
These are the only risks we are currently aware of, but there is always a possibility of 
unforeseen risks. 
Reproductive risks:  
There have been no reports of harm to pregnant patients or their babies from this 
intervention, and the risks posed by MACE to the general population are considered 
worse, so we allow pregnant patients to be a part of this study if they so choose. 
How will I know about new risks or important information about the study?  
We will tell you if we learn any new information that could change your mind about 
taking part in this study.  
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How can the study possibly benefit me?  
This study may or may not help you, but we hope it will decrease your risk for 
subsequent MACE in the future. Less risk for MACE means less need to seek healthcare, 
and less cost for your due to seeking this healthcare. We also hope that this will give us 
further insight into what is causing your Acute Coronary Syndrome and Nonobstructive 
coronary dysfunction so we can correctly diagnose you and better treat the cause. 
How can the study possibly benefit other people?  
The benefits to science and other people may include implementing and making 
accessible this additional testing in hospitals across the country so that others may receive 
a clear diagnosis for their nonobstructive coronary dysfunction and also receive the best 
treatment possible so they also have decreased risks of MACE. 
Are there any costs to participation?  
You will not have to pay for taking part in this study.  
Will I be paid for participation?  
You will not be paid for taking part in this study.  
How will you keep my data safe and private?  
We will keep all information we collect about you completely confidential. We will only 
share it with others if you agree to it or when we have to do it because U.S. or state law 
requires it. We will keep all data related to your care password protected in a secure 
database.  
When we publish the results of the research or talk about it in conferences, we will not 
use your name or other identifying information, such as your address or date of birth. We 
will also not share information about you with other researchers for future research.  
What Information Will You Collect About Me in this Study?  
The information we are asking to use and share is called “Protected Health Information.” 
It is protected by a federal law called the Privacy Rule of the Health Insurance Portability 
and Accountability Act (HIPAA). In general, we cannot use or share your health 
information for research without your permission. If you want, we can give you more 
information about the Privacy Rule. Also, if you have any questions about the Privacy 
Rule and your rights, you can speak to Yale Privacy Officer at 203-432-5919.  
The specific information about you and your health that we will collect, use, and share 
includes:  
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• Research study records  
• Medical and laboratory records of only those services provided in connection with  
this Study.  
• The entire research record and any medical records held by your other 
healthcare providers 
• Records about phone calls made as part of this research  
• Records about your study visit  
• Information obtained during this research regarding  
▪ Records about your medical condition ▪ Records about the study intervention 
How will you use and share my information?  
We will use your information to conduct the study described in this consent form.  
We may share your information with:  
• The U.S. Department of Health and Human Services (DHHS) agencies  
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Institutional Review Board (the committee that reviews, 
approves, and monitors research on human participants), who are responsible for 
ensuring research compliance. These individuals are required to keep all 
information confidential.  
• The U.S. Food and Drug Administration (FDA) This is done so that the FDA can 
review information about catheter, guidewire, and pressure-wire involved in 
this research. The information may also be used to meet the reporting 
requirements of drug regulatory agencies.  
• The study sponsor or manufacturer of study drug/device  
• Co-Investigators and other investigators  
• Study Coordinator and Members of the Research Team  
• Data and Safety Monitoring Boards and others authorized to monitor the conduct 
of the Study  
We will do our best to make sure your information stays private. But, if we share 
information with people who do not have to follow the Privacy Rule, your 
information will no longer be protected by the Privacy Rule. Let us know if you 
have questions about this. However, to better protect your health information, 
agreements are in place with these individuals and/or companies that require that 
they keep your information confidential.  
Why must I sign this document?  
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By signing this form, you will allow researchers to continue to use and disclose 
your information described above for this research study. This is to ensure that the 
information related to this research is available to all parties who may need it for 
research purposes. You always have the right to review and copy your health 
information in your medical record.  
What if I change my mind?  
The authorization to use and disclose your health information collected during 
your participation in this study will never expire. However, you may withdraw or 
take away your permission at any time. You may withdraw your permission by 
telling the study staff or by writing to Megan McCauley at the Yale University, 
New Haven, CT 06520.  
If you withdraw your permission, you will not be able to stay in this study but the 
care you get from your doctors outside this study will not change. No new health 
information identifying you will be gathered after the date you withdraw. 
Information that has already been collected may still be used and given to others 
until the end of the research study to ensure the integrity of the study and/or study 
oversight.  
What if I want to refuse or end participation before the study is over?  
Taking part in this study is your choice. You can choose to take part, or you can 
choose not to take part in this study. You also can change your mind at any time. 
Whatever choice you make, you will not lose access to your medical care or give 
up any legal rights or benefits.  
We would still treat you with standard therapy or, at your request, refer you to a clinic or 
doctor who can offer this treatment. Not participating or withdrawing later will not harm 
your relationship with your own doctors or with this institution.  
To withdraw from the study, you can call a member of the research team at any time and 
tell them that you no longer want to take part.  
The researchers may withdraw you from participating in the research if necessary. This 
may occur if you are discovered to not meet enrollment criteria, such as if you are: 
under 18 years of age, a prisoner, or ward of state.  
What will happen with my data if I stop participating?  
If you decide to stop participating in the study, all data and images associated with your 
name will be deleted from our database.  
Who should I contact if I have questions?  
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Please feel free to ask about anything you don't understand. 
If you have questions later or if you have a research-related problem, you can call the  
Principal Investigator at (413) 464-3510.  
If you have questions about your rights as a research participant, or you have complaints 
about this research, you call the Yale Institutional Review Boards at (203) 785-4688 or 
email hrpp@yale.edu.  
Authorization and Permission  
Your signature below indicates that you have read this consent document and that you 
agree to be in this study.  
We will give you a copy of this form.  
_____________________________     _____________________________       _______ 
Participant Printed Name       Participant Signature            Date  
_____________________________     _____________________________       _______ 
Person Obtaining Consent      Person Obtaining Consent            Date  
Printed Name           Signature  
_____________________________     _____________________________       _______ 
Legally Authorized Representative    LAR Signature            Date  
Name 






Complete if the participant is not fluent in English and an interpreter was used to obtain 
consent. Participants who do not read or understand English must not sign this full 
consent form, but instead sign the short form translated into their native 
language. This form should be signed by the investigator and interpreter only. If the 






Print name of interpreter: ______________________________________  
Signature of interpreter: ___________________________________ Date: _________  
An oral translation of this document was administered to the participant in 
_____________ (state language) by an individual proficient in English and 
____________ (state language).  
Print name of impartial witness: __________________________________  




Appendix 2: Participant MACE Form 
 
Definition of MACE 
Major Adverse Cardiac Events including: 
• Recurrent angina pain 
• Development of heart failure 
• Non-fatal infarction 
• Presentation to the Emergency Department with cardiovascular-related illness  
• Admission to the hospital for cardiovascular-related illness 
• Percutaneous coronary intervention (PCI)  
• Coronary artery bypass grafting (CABG) 
• Stroke 
• All-cause mortality 
 
 







2mo 3mo 4mo 5mo 6mo 7mo 8mo 9mo 10mo 11mo 12mo Total 
MACE              
Recurrent 
angina pain 
             
Heart 
failure 
             
Non-fatal 
Infarction 








             
PCI              
Stroke              
All-cause 
mortality 
             




*Directions: Please fill in the participant identification number in the blank above. 
Next, fill in which (if any) and how many MACE occur in the table above for each 
participant then calculate the total number of MACE.  
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Appendix 3: Sample Size Calculation 
Sample Size based on a dichotomous variable using the Power and Sample Size 
Calculator provided online by the Department of Biostatistics at Vanderbilt University 
(https://vbiostatps.app.vumc.org/ps/). 
- Type I error (alpha) = 0.05 
- Power = 0.80 (beta = 0.20) 
- Probability of outcome for control participant = p0 = 2% 
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